PAM
LRMR icon

Princeton Alpha Management’s Larimar Therapeutics LRMR Stock Holding History

Princeton Alpha Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,268
Closed -$182K – 881
2016
Q1 		$182K Buy
+2,268
New +$179K 0.03% 651

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Granahan Investment Management
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Princeton Alpha Management's LRMR Position: Q2 2016 in Review

Princeton Alpha Management sold out of Larimar Therapeutics (LRMR) in Q2 2016, closing a stake of 2,268 shares — an estimated $182K sold.

Princeton Alpha Management first reported a position in LRMR in Q1 2016 and held it in 1 quarter. The position peaked at $182K in Q1 2016. 73 funds tracked by Wall St. Rank hold LRMR as of Q2 2016.

  • Princeton Alpha Management reported no remaining Larimar Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 2,268 Larimar Therapeutics shares in Q2 2016, an estimated $182K.
  • Princeton Alpha Management first reported a position in Larimar Therapeutics in Q1 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Larimar Therapeutics position peaked at $182K in Q1 2016.
  • 73 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2016.

Based on Princeton Alpha Management's 13F filing for Q2 2016, filed 5 Aug 2016.